Lactose (India) Limited
LACTOSE.BO
Bombay Stock Exchange103.05
INR
+0.05
- -
Lactose (India) Limited
LACTOSE.BO
(Bombay Stock Exchange)
Recent
price
103.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lactose (India) Limited manufactures pharmaceutical-grade excipients and active pharmaceutical ingredients, primarily Lactose Monohydrate IP/BP/EP/USP-NF grades and Lactulose Concentrate USP and Lactulose Solution USP/EP; it also provides contract manufacturing services for solid dosage forms including dry granulated, film-coated, and lacquer-coated tablets, as well as liquid orals and finished formulations. The company, founded in 1991 and headquartered in Vadodara, Gujarat, India, operates a state-of-the-art facility with an annual production capacity of 10,000 MT for Lactose Monohydrate and 2,400 MT for Lactulose, making it the largest producer of Lactose Monohydrate in Southeast Asia and the first in Asia for Lactulose production. Its products serve the pharmaceutical industry for applications in tablets, treatments for constipation, hepatic encephalopathy, chronic liver disease, and as prebiotics, with additional exports of uncoated and blister-packed solid doses under NAFDAC approval and liquid filling lines holding Health Canada and WHO-GMP certifications. In recent developments, the company launched its Lactulose production facility in 2023, producing Lactulose Concentrate USP and Solution USP/EP for the first time in Asia, and commenced its own marketing and sales of Lactose Monohydrate in 2022 after previously relying on strategic alliances such as with Kerry Group of Ireland for 10,000 MT annual capacity. It continues long-term exclusive contract manufacturing for Sanofi India with a fully utilized capacity of 30 million tablets per month and expanded into liquid orals for clients like Dr. Reddy's, while planning capacity doublings to 20,000 MT for Lactose and 3,500-5,000 MT for Lactulose to target growth in South Asia, Africa, and prebiotic applications. In December 2024, Lactose India allotted 1.5 million warrants convertible into equity shares on a preferential basis following BSE approval, supporting its expansion initiatives. The company maintains operations focused on international pharmacopeia compliance, serving major clients including Abbott, Pfizer, Sun Pharma, and Lupin, with facilities strategically located 250 km from Nhava Sheva Port to supply Southeast Asia-Pacific, Middle East, North Africa, and Europe.